Calmark participates in Swiss Nordic Bio 2021 on 10-11 February
Anna Söderlund, CEO at Calmark will participate at Swiss Nordic Bio 2021, which will be held in digital format with more than 300 participants and 100 investors. The event will be live streamed and 1-to-1 meetings will be held virtually.
Swiss Nordic Bio is a high-level partnering and investor conference aimed at connecting healthcare innovations, investors and industry. The event carries 13 years of tradition, previously Swiss Scandinavian Bio-Business Seminar, and is organised by the Nordic countries in cooperation with Swiss partners. Business Sweden and Vator Securities are the co-hosts of this year’s digital version of this event.
"It will be very interesting to meet with European participants to assess how Calmark is perceived in an international investor context”, says Anna Söderlund, CEO. "In the private placement at the end of last year, several Danish and Norwegian actors chose to invest in Calmark and I look forward to welcoming more!”
Find out more about the event: https://www.swissnordicbio.com
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark develops a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.
